PETACH TIKVA, Israel, March 10, 2017 /PRNewswire/ --
Emerald Medical Applications Corp. (OTCQB: MRLA) ("Emerald" or the "Company"), an Israeli-based company engaged in the development and sale of DermaCompare™, its proprietary artificial intelligence technology and application for the early diagnosis of melanoma and other skin cancers, today announced that Publicis Groupe completed the purchase of 1,315,563 shares of Emerald's common stock, representing a total investment of $526,225.20, a based upon the agreed purchase price of $0.40 per share.
Publicis Groupe's investment in Emerald, which was made after significant due diligence regarding the Company and its DermaCompare™ skin cancer screening application, was the result of the Company being awarded the Grand Prize of 500,000 Euros over 3,500 other competing tech companies at Publicis Groupe's "Publicis 90" Initiative at the Viva Technology event held in Paris, France in early July 2016. after being selected.
Adi Zamir, the Company's Chief Executive Officer, commented on the investment, "We are grateful for the continued support we have received since winning the Publicis 90 Grand Prize. We firmly believe that this equity investment by Publicis is further validation of our DermaCompare platform which combines military-grade surveillance technology, artificial intelligence, crowdsourced data and a cloud-based mobile platform with a free, intuitive app to facilitate the detection of cancerous moles and skin anomalies with a simple digital camera. The capital provided, along with mentoring we will receive from the Publicis team will help ensure that we have the resources we need as we prepare to commercialize DermaCompare. We are honored by this faith in our future, which we also believe to be very bright!"
About Emerald Medical Applications Corp
Emerald Medical Applications is an Israeli-based medical technology company that utilizes proprietary military image processing technology and state of the art data analytics to improve the analysis of medical images. Emerald's flagship solution, DermaCompare™, is an FDA Class #1 approved, HIPPA-compliant, skin cancer (melanoma) screening platform that enables physicians to identify and monitor changes in their patients' skin health, specifically the early detection of cancerous moles and skin anomalies.
The DermaCompare™ patient application is available in Mac or Android based platforms and works using virtually any digital camera, including cell phones, iPads, tablets and other similar devices, to take Total Body Photography ("TBP") images and, in real-time, transmit these images for dermatological evaluation and identification of suspicious moles, lesions and other skin conditions. These images are then compared using Emerald's cloud database, as well as the patient's previous Total Body Photography images, which will dramatically enhance a physician's ability to detect Melanoma earlier, more accurately and more efficient than other means of diagnosis
For more information, visit: http://www.dermacompare.com/
Notice Regarding Forward-Looking Statements
This press release may contain forward-looking statements, about Emerald's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, Emerald or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by Emerald with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of Emerald's authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Emerald's actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause Emerald's actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements, including, but not limited to, the factors summarized in Emerald's filings with the SEC. In addition, Emerald operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. Emerald does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise. Reference is made to the disclosure under "risk factors" included in our Registration Statement on Form S-1 which was declared effective by the U.S. Securities and Exchange Commission onJanuary 20, 2016.
Adi Zamir, CEO
SOURCE Emerald Medical Applications Corp.